FDA warns against ‘do it yourself’ gene therapy kits Wed, 22 Nov 2017 18:15:11 +0000 The U.S. Food and Drug Administration has issued a stern warning against the use of “do it yourself” gene therapy kits, pushing back against a nascent “biohacker” movement that seeks to make experimental medicines and technologies available to the masses, often by circumventing regulators. A statement posted on the FDA’s website on Tuesday cautions that it is illegal to sell gene therapy products and kits intended for self-administration. Gene therapy involves inserting new, healthy genes into cells to cure diseases that are caused by faulty genes.
Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team Tue, 14 Nov 2017 12:00:00 +0000 CAMBRIDGE, Mass., Nov. 14, 2017 /PRNewswire/ -- Torque, an immuno-oncology company developing Deep Primed™ cell therapies that direct and evoke immune responses in the tumor microenvironment, today announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed with $25 million in Series A capital by Flagship Pioneering. The Torque platform makes it possible to anchor powerful stimulatory cytokines, antibodies, and small molecules directly to immune cells to direct their activity and increase their efficacy and durability in the "hostile" tumor microenvironment, without systemic exposure.
Editas Medicine Keeps Moving Forward Thu, 09 Nov 2017 14:00:00 +0000 The biotech offered steady progress and no big surprises in its latest quarter -- and that's a good thing.
Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : November 9, 2017 Thu, 09 Nov 2017 12:53:52 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Editas Medicine, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Barclays: Editas Medicine On Track To File New Drug App Next Year Wed, 08 Nov 2017 21:24:20 +0000 Editas Medicine Inc (NASDAQ: EDIT ) reported third-quarter earnings Tuesday and it failed to meet Wall Street expectations. The Analyst Barclays' Gena Wang . The Rating Wang maintained an Overweight on ...
Editas reports 3Q loss Tue, 07 Nov 2017 21:13:39 +0000 On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 64 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Editas Medicine Announces Third Quarter 2017 Results and Update Tue, 07 Nov 2017 21:03:00 +0000 CAMBRIDGE, Mass., Nov. 07, 2017-- Editas Medicine, Inc., a leading genome editing company, today reported financial results for the third quarter ended September 30, 2017, and provided an update on recent ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.42 (median winner: 1.53)
Liquidity: 1.99% (median winner: 1.18%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.